Premium
Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT 1 receptor and NADPH oxidase activity
Author(s) -
Siragy Helmy M.,
Huang Jiqian
Publication year - 2008
Publication title -
experimental physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.925
H-Index - 101
eISSN - 1469-445X
pISSN - 0958-0670
DOI - 10.1113/expphysiol.2007.040550
Subject(s) - medicine , endocrinology , angiotensin ii receptor type 1 , valsartan , mesangium , nadph oxidase , immunostaining , renin–angiotensin system , streptozotocin , angiotensin ii , angiotensin receptor , receptor , diabetic nephropathy , chemistry , kidney , diabetes mellitus , nephropathy , immunohistochemistry , oxidative stress , blood pressure
Recent studies have demonstrated the presence of the (pro)renin receptor (PRR) in the glomerular mesangium and the subendothelial layer of the renal arteries. We hypothesized that diabetes upregulates PRR expression through enhanced angiotensin subtype 1 (AT 1 ) receptor–NADPH oxidase cascade activity. Using real‐time polymerase chain reaction, Western blot analysis and immunostaining, we studied renal localization of the PRR in the streptozotocin‐induced diabetic rat model and in response to 1 week of treatment with the AT 1 receptor blocker valsartan (10 mg kg −1 day −1 ), the angiotensin AT 2 receptor blocker PD123319 (0.5 mg kg −1 day −1 ) or the NADPH oxidase inhibitor diphenylene iodonium (DPI; 0.5 mg kg −1 day −1 ) 6 weeks post‐induction of diabetes. Both PRR mRNA and protein were expressed constitutively in the kidneys of normal rat renal cortex and medulla, mainly in glomerular mesangium, proximal, distal and collecting tubules. Compared with normal rats (100%), diabetic rats demonstrated an increase in renal PRR mRNA (184%), protein (228%) and immunostaining. Valsartan and DPI prevented the increase in the PRR mRNA (106 and 126%, respectively), protein (97 and 140%, respectively) and immunostaining that was seen in the kidneys of diabetic rats. The AT 2 blocker PD123319 did not have significant effects on PRR mRNA (157%) or protein expression (200%) in the kidneys of diabetic rats. These results demonstrate that the PRR is constitutively expressed in renal glomeruli and tubules. Expression of the PRR is upregulated in diabetes via enhancement of AT 1 receptor–NADPH oxidase activity.